Ann Pharmacol Pharm | Volume 2, Issue 10 | Review Article | Open Access

Controlled-Release Preparation Containing Meglitinide for Treatment of Type-II Diabetes Mellitus

Chisato Makino^*

Institute for Innovation, Ajinomoto Co, Japan

^*Correspondance to: Chisato Makino 

Abstract

Meglitinides promote pancreas insulin secretion, and have a short half-life in plasma; they are often termed "short-acting-type insulin secretagogues”. They primarily control postprandial blood glucose. On the basis of these characteristics, various controlled-release preparations containing meglitinides are currently being developed to achieve precise and/or timely control of blood glucose, or to reduce the dosing frequency, or to enable a more convenient administration route. If approved, it is hoped that they will increase quality of life for diabetes patients.

Keywords:

Meglitinides; Blood glucose level; Controlled-release preparation

Citation:

Makino C. Controlled-Release Preparation Containing Meglitinide for Treatment of Type-II Diabetes Mellitus. Ann Pharmacol Pharm. 2017; 2(10): 1104.